Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyrilutamide solution in Chinese adults with androgenetic alopecia – long-term safety
CTR20231724Phase 3Completed
- Sponsor
- Suzhou Kaixi Pharmaceutical
- Start
- Jun 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of pyrilutamide in androgenetic alopecia (AGA), sponsored by Suzhou Kaixi Pharmaceutical. Started Jun 2023; status: completed.
02
Drugs
pyrilutamide
03
Conditions
androgenetic alopecia (AGA)
Beyond the preview
Go deeper on CTR20231724.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20231724.